Goldman Sachs: Eli Lilly's Shares May Surge By 140% With GLP-1 Drug Boom

Eli Lilly and Co. LLY could witness a 140% surge in its shares, as predicted by Goldman Sachs. The growth is anticipated to be driven by an increased demand for GLP-1 weight loss and diabetes drugs.

What Happened: Goldman Sachs’ latest research suggests a bright future for Eli Lilly, as reported by Business Insider on Tuesday. The bank predicts that by 2028, GLP-1 drugs, including Eli Lilly’s Mounjaro and Zepbound, will be consumed by nearly 68 million Americans.

The banking giant believes that the potential of GLP-1 drugs has been underestimated, which could potentially skyrocket their revenues to an astonishing $400 billion. This is four times higher than Wall Street’s current estimates. Goldman Sachs likens the potential of these drugs to the transformative effects of Apple’s iPhone and Amazon’s e-commerce business.

See Also: Mark Cuban’s Cost Plus Drugs Gets Medication Elon Musk Asked About 6 Months Ago: ‘Still Ready To Save Tesla, SpaceX And X a F**kton of Money’

Goldman Sachs also advised investors to keep an eye on key GLP-1 studies, namely SYNCHRONIZA-CVOT, REDEFINE-3, and SURMOUNT-MMO. These studies are expected to increase the demand for GLP-1 drugs by 9 million people.

Despite the bullish outlook, Goldman Sachs maintains a “Neutral” rating for Eli Lilly and sets a $600 price target, indicating a potential 5% upside from its current levels.

Why It Matters: Earlier this year, Eli Lilly’s stock witnessed a significant rise as the company capitalized on the growing trend of obesity drugs. The company’s GLP-1 drug, Mounjaro, which is presently indicated for treating Type 2 diabetes, has been attracting more investors. This is due to its upside potential, GLP-1, or glucagon-like peptide-1 agonists, are a type of drug used for treating Type 2 diabetes and obesity. The increasing demand for these drugs could contribute significantly to Eli Lilly’s growth.

Read Next: Why is Prostate Cancer Focused Lantheus (LNTH) Stock Trading Lower Today?

Image by Mohammed_Al_Ali via Shutterstock


Engineered by Benzinga Neuro, Edited by Pooja Rajkumari


The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CareMarketsAnalyst RatingsGeneralEli Lilly & Co.GLP-1 drugsStories That Matter
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!